{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:41:32Z","timestamp":1793450492358,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930073"],"award-info":[{"award-number":["81930073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203037"],"award-info":[{"award-number":["82203037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-52139-2","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T14:02:32Z","timestamp":1725976952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3645-2634","authenticated-orcid":false,"given":"Yue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-7471","authenticated-orcid":false,"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4877-0930","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-0764","authenticated-orcid":false,"given":"Danwen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcellus","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-1492","authenticated-orcid":false,"given":"Jun","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueren","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanila","family":"Fernandez Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-4887","authenticated-orcid":false,"given":"Roberto","family":"Vendramin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-0601","authenticated-orcid":false,"given":"Yihua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9338-2463","authenticated-orcid":false,"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-0914","authenticated-orcid":false,"given":"Kevin","family":"Litchfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1928","authenticated-orcid":false,"given":"Zhiwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-257X","authenticated-orcid":false,"given":"Haiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"52139_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"52139_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115\u2013132 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"52139_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"52139_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629\u2013640 (2017).","journal-title":"N. Engl. J. Med."},{"key":"52139_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon, B. J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167\u20132177 (2014).","journal-title":"N. Engl. J. Med."},{"key":"52139_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 20, 1691\u20131701 (2019).","journal-title":"Lancet Oncol."},{"key":"52139_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard, D. et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 18, 1307\u20131316 (2017).","journal-title":"Lancet Oncol."},{"key":"52139_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"52139_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"52139_CR10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"52139_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"52139_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.036","volume":"79","author":"B Shum","year":"2022","unstructured":"Shum, B., Larkin, J. & Turajlic, S. Predictive biomarkers for response to immune checkpoint inhibition. Semin. Cancer Biol. 79, 4\u201317 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"52139_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0022-5223(19)40289-4","volume":"70","author":"N Martini","year":"1975","unstructured":"Martini, N. & Melamed, M. R. Multiple primary lung cancers. J. Thorac. Cardiovasc Surg. 70, 606\u2013612 (1975).","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"52139_CR14","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1007\/s00330-021-08464-x","volume":"32","author":"JW Huo","year":"2022","unstructured":"Huo, J. W. et al. Radiological classification, gene-mutation status, and surgical prognosis of synchronous multiple primary lung cancer. Eur. Radio. 32, 4264\u20134274 (2022).","journal-title":"Eur. Radio."},{"key":"52139_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1183\/09031936.00105911","volume":"39","author":"A Warth","year":"2012","unstructured":"Warth, A. et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur. Respir. J. 39, 1437\u20131442 (2012).","journal-title":"Eur. Respir. J."},{"key":"52139_CR16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.athoracsur.2013.04.142","volume":"96","author":"YC Yu","year":"2013","unstructured":"Yu, Y. C. et al. Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? Ann. Thorac. Surg. 96, 1966\u20131974 (2013).","journal-title":"Ann. Thorac. Surg."},{"key":"52139_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/jnci\/djp059","volume":"101","author":"AF Gazdar","year":"2009","unstructured":"Gazdar, A. F. & Minna, J. D. Multifocal lung cancers\u2013clonality vs field cancerization and does it matter? J. Natl Cancer Inst. 101, 541\u2013543 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"52139_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13200","volume":"7","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat. Commun. 7, 13200 (2016).","journal-title":"Nat. Commun."},{"key":"52139_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/JTO.0b013e3181c8cb95","volume":"5","author":"AM Maeshima","year":"2010","unstructured":"Maeshima, A. M. et al. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J. Thorac. Oncol. 5, 333\u2013339 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"52139_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PAS.0b013e318190157c","volume":"33","author":"AC Borczuk","year":"2009","unstructured":"Borczuk, A. C. et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am. J. Surg. Pathol. 33, 462\u2013469 (2009).","journal-title":"Am. J. Surg. Pathol."},{"key":"52139_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13460-3","volume":"10","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat. Commun. 10, 5472 (2019).","journal-title":"Nat. Commun."},{"key":"52139_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22890-x","volume":"12","author":"H Dejima","year":"2021","unstructured":"Dejima, H. et al. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat. Commun. 12, 2722 (2021).","journal-title":"Nat. Commun."},{"key":"52139_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10877-8","volume":"10","author":"X Hu","year":"2019","unstructured":"Hu, X. et al. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat. Commun. 10, 2978 (2019).","journal-title":"Nat. Commun."},{"key":"52139_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jtho.2019.01.017","volume":"14","author":"A Mansuet-Lupo","year":"2019","unstructured":"Mansuet-Lupo, A. et al. Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J. Thorac. Oncol. 14, 844\u2013856 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"52139_CR25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611\u20131624.e24 (2017).","journal-title":"Cell"},{"key":"52139_CR26","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-13-2664","volume":"74","author":"D Endesfelder","year":"2014","unstructured":"Endesfelder, D. et al. Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. Cancer Res. 74, 4853\u20134863 (2014).","journal-title":"Cancer Res."},{"key":"52139_CR27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978\u2013985 (2018).","journal-title":"Nat. Med."},{"key":"52139_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"52139_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"52139_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s42256-023-00619-3","volume":"5","author":"Y Gao","year":"2023","unstructured":"Gao, Y. et al. Pan-Peptide Meta Learning for T-cell receptor\u2013antigen binding recognition. Nat. Mach. Intell. 5, 236\u2013249 (2023).","journal-title":"Nat. Mach. Intell."},{"key":"52139_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173, 595\u2013610.e11 (2018).","journal-title":"Cell"},{"key":"52139_CR32","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1158\/1078-0432.CCR-17-0232","volume":"23","author":"AR Thierry","year":"2017","unstructured":"Thierry, A. R. et al. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin. Cancer Res. 23, 4578\u20134591 (2017).","journal-title":"Clin. Cancer Res."},{"key":"52139_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","volume":"4","author":"S Misale","year":"2014","unstructured":"Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269\u20131280 (2014).","journal-title":"Cancer Discov."},{"key":"52139_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","volume":"2","author":"JI Griffiths","year":"2021","unstructured":"Griffiths, J. I. et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4\/6 therapy. Nat. Cancer 2, 658\u2013671 (2021).","journal-title":"Nat. Cancer"},{"key":"52139_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","volume":"19","author":"A Friedlaender","year":"2022","unstructured":"Friedlaender, A. et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat. Rev. Clin. Oncol. 19, 51\u201369 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"52139_CR36","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/0008-5472.CAN-21-1526","volume":"81","author":"H Han","year":"2021","unstructured":"Han, H. et al. Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Res. 81, 5311\u20135324 (2021).","journal-title":"Cancer Res"},{"key":"52139_CR37","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/s12276-022-00896-9","volume":"54","author":"J Zhu","year":"2022","unstructured":"Zhu, J. et al. Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics. Exp. Mol. Med 54, 2060\u20132076 (2022).","journal-title":"Exp. Mol. Med"},{"key":"52139_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202100082","volume":"5","author":"Y He","year":"2021","unstructured":"He, Y. et al. Mechanisms of progression and heterogeneity in multiple nodules of lung adenocarcinoma. Small Methods 5, e2100082 (2021).","journal-title":"Small Methods"},{"key":"52139_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103315","volume":"66","author":"K Chen","year":"2021","unstructured":"Chen, K. et al. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. EBioMedicine 66, 103315 (2021).","journal-title":"EBioMedicine"},{"key":"52139_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s43657-022-00084-9","volume":"3","author":"D Morazan-Fernandez","year":"2023","unstructured":"Morazan-Fernandez, D., Mora, J. & Molina-Mora, J. A. In Silico pipeline to identify tumor-specific antigens for cancer immunotherapy using exome sequencing data. Phenomics 3, 130\u2013137 (2023).","journal-title":"Phenomics"},{"key":"52139_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw, P. et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11, 39\u201351 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"52139_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.lungcan.2012.04.003","volume":"77","author":"J Arai","year":"2012","unstructured":"Arai, J. et al. Clinical and molecular analysis of synchronous double lung cancers. Lung Cancer 77, 281\u2013287 (2012).","journal-title":"Lung Cancer"},{"key":"52139_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis, W. D. et al. International association for the study of lung cancer\/american thoracic society\/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244\u2013285 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"52139_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R., Klein, A. M. & Scrublet Computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e9 (2019).","journal-title":"Cell Syst."},{"key":"52139_CR45","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"52139_CR46","unstructured":"Tickle, T. I., Georgescu, C., Brown, M. & Haas, B. inferCNV of the Trinity CTAT Project. (Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA, 2019) https:\/\/github.com\/broadinstitute\/inferCNV."},{"key":"52139_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-021-07739-3","volume":"22","author":"S Kurtenbach","year":"2021","unstructured":"Kurtenbach, S., Cruz, A. M., Rodriguez, D. A., Durante, M. A. & Harbour, J. W. Uphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data. BMC Genomics 22, 419 (2021).","journal-title":"BMC Genomics"},{"key":"52139_CR48","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/0008-5472.CAN-22-3140","volume":"83","author":"F Fan","year":"2023","unstructured":"Fan, F. et al. Elevated mast cell abundance is associated with enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma. Cancer Res. 83, 2690\u20132703 (2023).","journal-title":"Cancer Res"},{"key":"52139_CR49","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"52139_CR50","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997v2 [q-bio.GN] (2013)."},{"key":"52139_CR51","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet 43, 491\u2013498 (2011).","journal-title":"Nat. Genet"},{"key":"52139_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"52139_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"52139_CR54","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1093\/bioinformatics\/btaa264","volume":"36","author":"CA Darby","year":"2020","unstructured":"Darby, C. A., Stubbington, M. J. T., Marks, P. J., Martinez Barrio, A. & Fiddes, I. T. scHLAcount: allele-specific HLA expression from single-cell gene expression data. Bioinformatics 36, 3905\u20133906 (2020).","journal-title":"Bioinformatics"},{"key":"52139_CR55","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"52139_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res. 9, 47 (2020).","journal-title":"F1000Res"},{"key":"52139_CR57","doi-asserted-by":"publisher","unstructured":"Zhao, Y. & Wang, J. Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages (Paper). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.12878282 (2024).","DOI":"10.5281\/zenodo.12878282"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52139-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:03:47Z","timestamp":1725980627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52139-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52139"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52139-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3272278\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: K.L. has the following disclosures (all outside of the submitted work): patent on indel burden and CPI response pending, patent on ctDNA minimal residual disease calling methods; speaker fees from Roche tissue diagnostics and Ellipses pharma; research funding from CRUK TDL\/Ono\/LifeArc alliance and Genesis Therapeutics; and consulting roles with Monopteros Therapeutics, Kynos Therapeutics and Tempus Labs, Inc. M.A. is supported by the City of London Centre Clinical Academic Training Programme (Year 3, SEBSTF-2021\\100007). All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7928"}}